{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:19:15Z","timestamp":1768015155201,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chinese Association of Cardiology","award":["CSCF2020B04"],"award-info":[{"award-number":["CSCF2020B04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>With the expanded utilization of transcatheter aortic valve implantation (TAVI) to younger and lower surgical risk patients with severe aortic stenosis (AS), optimal medical therapy after TAVI procedure has become the main concern. Renin-angiotensin system inhibitors (RASi) are widely utilized in the area of cardiovascular disease including heart failure and myocardial infarction and revealed the ability to reverse left ventricular (LV) remodeling. Interests have, thus, been drawn in investigating whether the prescription of RASi after the TAVI procedure can prevent or reverse cardiac remodeling and improve long-term clinical outcomes. No recommendation regarding the prescription of RASi after TAVI is proposed yet due to the lack of evidence from randomized controlled trials, especially in the Chinese population. We, therefore, designed this randomized controlled trial to explore the effect of adding fosinopril to standard care in patients who underwent a successful TAVI procedure on the LV remodeling.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 200 post-TAVI patients from seven academic hospitals across China will be recruited and randomized with a ratio of 1:1 to receive standard care or standard care plus fosinopril. Follow-up visits will take place at 30\u2009days, 3\u2009months, 6\u2009months, 12\u2009months, and 24\u2009months from randomization to assess the clinical symptoms, any adverse events, cardiac function, and quality of life. Cardiac magnetic resonance will be performed at baseline and repeated at the 24-month follow-up visit to assess LV remodeling.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will provide evidence regarding medical therapy for AS patients who underwent TAVI and filling the gap in the Chinese population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Chinese Clinical Trial Registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=120299\">ChiCTR2100042266<\/jats:ext-link>. Registered on 17 January 2021<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05411-5","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T08:03:26Z","timestamp":1626595406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Yan Biao","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-5965","authenticated-orcid":false,"given":"Congying","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanweixiang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyuan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiafu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,18]]},"reference":[{"issue":"9667","key":"5411_CR1","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(09)60211-7","volume":"373","author":"BA Carabello","year":"2009","unstructured":"Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373(9667):956\u201366.","journal-title":"Lancet"},{"issue":"18","key":"5411_CR2","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","volume":"380","author":"MJ Mack","year":"2019","unstructured":"Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695\u2013705. https:\/\/doi.org\/10.1056\/NEJMoa1814052.","journal-title":"N Engl J Med"},{"issue":"8 Pt 1","key":"5411_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.jcmg.2019.02.034","volume":"12","author":"TA Treibel","year":"2019","unstructured":"Treibel TA, Badiani S, Lloyd G, Moon JC. Multimodality imaging markers of adverse myocardial remodeling in aortic stenosis. J Am Coll Cardiol Img. 2019;12(8 Pt 1):1532\u201348. https:\/\/doi.org\/10.1016\/j.jcmg.2019.02.034.","journal-title":"J Am Coll Cardiol Img"},{"issue":"6","key":"5411_CR4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jcin.2014.02.011","volume":"7","author":"BR Lindman","year":"2014","unstructured":"Lindman BR, Stewart WJ, Pibarot P, Hahn RT, Otto CM, Xu K, et al. Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. JACC Cardiovasc Interv. 2014;7(6):662\u201373. https:\/\/doi.org\/10.1016\/j.jcin.2014.02.011.","journal-title":"JACC Cardiovasc Interv"},{"key":"5411_CR5","doi-asserted-by":"publisher","unstructured":"Li YM, Mei FY, Yao YJ, Tsauo JY, Peng Y, Chen M. Causes and predictors of readmission after transcatheter aortic valve implantation : A meta-analysis and systematic review. Herz. 2021;46(Suppl 1):1-8. English.\u00a0 https:\/\/doi.org\/10.1007\/s00059-019-04870-6. Epub 2019 Dec 5.","DOI":"10.1007\/s00059-019-04870-6"},{"key":"5411_CR6","doi-asserted-by":"publisher","first-page":"j4","DOI":"10.1136\/bmj.j4","volume":"356","author":"S Bangalore","year":"2017","unstructured":"Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ. 2017;356:j4.","journal-title":"BMJ"},{"issue":"16","key":"5411_CR7","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147\u2013239. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"5411_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjcard.2010.04.028","volume":"106","author":"JS Dahl","year":"2010","unstructured":"Dahl JS, Videbaek L, Poulsen MK, Pellikka PA, Veien K, Andersen LI, et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol. 2010;106(5):713\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2010.04.028.","journal-title":"Am J Cardiol"},{"issue":"21","key":"5411_CR9","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1001\/jama.2018.18077","volume":"320","author":"T Inohara","year":"2018","unstructured":"Inohara T, Manandhar P, Kosinski AS, Matsouaka RA, Kohsaka S, Mentz RJ, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA. 2018;320(21):2231\u201341. https:\/\/doi.org\/10.1001\/jama.2018.18077.","journal-title":"JAMA"},{"issue":"5","key":"5411_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jacc.2019.05.055","volume":"74","author":"T Rodriguez-Gabella","year":"2019","unstructured":"Rodriguez-Gabella T, Catal\u00e1 P, Mu\u00f1oz-Garc\u00eda AJ, Nombela-Franco L, Del Valle R, Guti\u00e9rrez E, et al. Renin-angiotensin system inhibition following transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74(5):631\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"5411_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.7326\/M13-1505","volume":"161","author":"SS Goel","year":"2014","unstructured":"Goel SS, Aksoy O, Gupta S, Houghtaling PL, Tuzcu EM, Marwick T, et al. Renin-angiotensin system blockade therapy after surgical aortic valve replacement for severe aortic stenosis: a cohort study. Ann Intern Med. 2014;161(10):699\u2013710. https:\/\/doi.org\/10.7326\/M13-1505.","journal-title":"Ann Intern Med"},{"issue":"19","key":"5411_CR12","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1093\/eurheartj\/ehs255","volume":"33","author":"AP Kappetein","year":"2012","unstructured":"Kappetein AP, Head SJ, G\u00e9n\u00e9reux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012;33(19):2403\u201318. https:\/\/doi.org\/10.1093\/eurheartj\/ehs255.","journal-title":"Eur Heart J"},{"issue":"8","key":"5411_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/heartjnl-2017-311738","volume":"104","author":"T Ochiai","year":"2018","unstructured":"Ochiai T, Saito S, Yamanaka F, Shishido K, Tanaka Y, Yamabe T, et al. Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation. Heart. 2018;104(8):644\u201351. https:\/\/doi.org\/10.1136\/heartjnl-2017-311738.","journal-title":"Heart"},{"issue":"5","key":"5411_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245\u201355. https:\/\/doi.org\/10.1016\/S0735-1097(00)00531-3.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"5411_CR15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"M Galderisi","year":"2017","unstructured":"Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18(12):1301\u201310.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"5411_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","volume":"22","author":"J Schulz-Menger","year":"2020","unstructured":"Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing. J Cardiovasc Magn Reson. 2020;22(1):19.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"5411_CR17","doi-asserted-by":"publisher","first-page":"e020255","DOI":"10.1136\/bmjopen-2017-020255","volume":"8","author":"IJ Amat-Santos","year":"2018","unstructured":"Amat-Santos IJ, Catal\u00e1 P, Del Hoyo FD, Fernandez-Diaz JA, Alonso-Briales JH, Del Trigo M, et al. Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study. BMJ Open. 2018;8(2):e020255.","journal-title":"BMJ Open"},{"key":"5411_CR18","unstructured":"Aboyans V, Magne J. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03315832. Accessed 1 Jun 2021."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05411-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05411-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05411-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T08:09:20Z","timestamp":1626595760000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05411-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,18]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5411"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05411-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,18]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the institutional ethics committee of West China Hospital of Sichuan University and the local medical ethics committee of each participating center. Written informed consent will be collected from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"Dr. Chen and Feng are consultants and proctors for Venus MedTech, MicroPort, and TaurusOne. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"462"}}